Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
US11738026B2 · kind B2 · utility
0Cited by
54References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2020 |
| Grant date | Aug 29, 2023 |
| Priority date | — |
| Expiry date | Aug 13, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with JAK2 and/or ALK2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.